Role of complement activation in hypersensitivity reactions to doxil and HYNICPEG liposomes: Experimental and clinical studies

被引:162
作者
Szebeni, J [1 ]
Baranyi, L
Savay, S
Milosevits, J
Bunger, R
Laverman, P
Metselaar, JM
Storm, G
Chanan-Khan, A
Liebes, L
Muggia, FM
Cohen, R
Barenholz, Y
Alving, CR
机构
[1] Walter Reed Army Inst Res, Silver Spring, MD USA
[2] Uniformed Serv Univ Hlth Sci, Dept Anatomy Physiol & Genet, Bethesda, MD USA
[3] Univ Nijmegen, Ctr Med, Dept Nucl Med, Nijmegen, Netherlands
[4] Univ Utrecht, Utrecth Inst Pharmaceut Sci, Utrecht, Netherlands
[5] NYU, Ctr Med, Kaplan Comprehens Canc Ctr, New York, NY USA
[6] Hebrew Univ Jerusalem, Hadassah Med Sch, Lab Membrane & Liposome Res, Jerusalem, Israel
关键词
D O I
10.1081/LPR-120004790
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pegylated liposomal doxorubicin (Doxil) and Tc-99m-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 18 条
  • [1] Safety aspects of pegylated liposomal doxorubicin in patients with cancer
    Alberts, DS
    Garcia, DJ
    [J]. DRUGS, 1997, 54 (Suppl 4) : 30 - 35
  • [2] Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease
    Brouwers, AH
    De Jong, DJ
    Dams, ETM
    Oyen, WJG
    Boerman, OC
    Laverman, P
    Naber, THJ
    Storm, G
    Corstens, FHM
    [J]. JOURNAL OF DRUG TARGETING, 2000, 8 (04) : 225 - 233
  • [3] deMarie S, 1996, LEUKEMIA, V10, pS93
  • [4] Dezube BJ, 1996, DOXIL CLIN SERIES, V1, P1
  • [5] GABIZON A, 1994, CANCER RES, V54, P987
  • [6] CLINICAL-STUDIES OF LIPOSOME-ENCAPSULATED DOXORUBICIN
    GABIZON, A
    ISACSON, R
    LIBSON, E
    KAUFMAN, B
    UZIELY, B
    CATANE, R
    BENDOR, CG
    RABELLO, E
    CASS, Y
    PERETZ, T
    SULKES, A
    CHISIN, R
    BARENHOLZ, Y
    [J]. ACTA ONCOLOGICA, 1994, 33 (07) : 779 - 786
  • [7] Gabizon A.A., 1998, LONG CIRCULATING LIP, P155
  • [8] Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
    Gabizon, AA
    [J]. CANCER INVESTIGATION, 2001, 19 (04) : 424 - 436
  • [9] Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
    Koukourakis, MI
    Koukouraki, S
    Giatromanolaki, A
    Archimandritis, SC
    Skarlatos, J
    Beroukas, K
    Bizakis, JG
    Retalis, G
    Karkavitsas, N
    Helidonis, ES
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3512 - 3521
  • [10] Lyass O, 2001, CLIN CANCER RES, V7, P3040